Pneumococcal polysaccharide vaccines (PPVs) and conjugate vaccines (PCVs), of which
PPV23 and PCV13 are the current front runners, have had a significant, beneficial impact on …

Clin Microbiol Infect 2012; 18 (Suppl. 5): 7–14 Abstract Streptococcus pneumoniae causes
different types of acute, invasive and non‐invasive clinical infections, being the most …

This report compiles and summarizes all published recommendations from CDC's Advisory
Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults …

Background The increasing use of highly active antiretroviral therapy (HAART) and
pneumococcal immunization along with shifting community exposures may have altered the …

In the combined antiretroviral therapy era, HIV-infected patients remain a vulnerable
population for the onset of bloodstream infections (BSI). Worldwide, nontyphoid …

Objectives: To examine invasive pneumococcal disease (IPD) incidence, the impact of the 7-
valent pneumococcal conjugate vaccines (PCV7s) programme on the distribution of …

Background The objective of this systematic review and meta-analysis was to summarise the
literature regarding the immunogenicity of pneumococcal conjugate vaccines (PCV) and …

Background. Persons with human immunodeficiency virus (HIV) infection are at increased
risk of pneumococcal disease. We evaluated the safety and immunogenicity of 13-valent …

Streptococcus pneumoniae is the leading bacterial opportunistic infection in HIV-infected
individuals. Anti-retroviral treatment (ART) of HIV-infected individuals reduces their risk of …

Vaccination is a critical component for ensuring the health of those living with the human
immunodeficiency virus (HIV) by protection against vaccine-preventable diseases. Since …